Adamax is a synthetic heptapeptide derived from Semax with an added adamantane group, and users take it off‑label for cognitive enhancement and neuroprotection. In the community the most common regimen is 500 µg per day, with doses reported from 125 µg up to 1.5 mg; a clinician source recommends 300 µg daily subcutaneously for 4–8 weeks. The only clear limitation is that it has no FDA‑approved indication, so all human use is off‑label or compounded, and injection‑site reactions have not emerged as a consistent issue.
Data last updated
Measured on 3 of 6 axes
Evidence shape
No registered clinical trials extracted for Adamax yet.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How ADAMAX is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
The reported dosing regimen for ADAMAX in this tier consists of a 300‑microgram amount administered subcutaneously on a daily schedule.
Users typically administer ADAMAX subcutaneously at around 500 mcg, though reported amounts span from 50 mcg to 1.5 mg; one subset takes 300 mcg twice daily, while most reports do not specify a frequency.